


RECEIVED  
CENTRAL FAX CENTER

JAN 25 2007

Applicants: Cornelia J. Forster et al.  
Application No.: 10/632,340AMENDMENTS TO THE CLAIMS

Please replace all prior versions and listings of claims with the amended claims as follows:

1. (Previously presented) A compound of formula I:



I

or a pharmaceutically acceptable salt thereof, wherein:

W is nitrogen;

R<sup>1</sup> is selected from hydrogen or fluorine; and

R<sup>y</sup> is a C<sub>1-4</sub> aliphatic group, optionally substituted with N(R<sup>2</sup>)<sub>2</sub> or a 5-6 membered saturated ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein:

each R<sup>2</sup> is independently selected from hydrogen or a C<sub>1-3</sub> aliphatic group optionally substituted with OH, N(R<sup>3</sup>)<sub>2</sub>, or a 5-6 membered saturated ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur; and wherein:


each R<sup>3</sup> is independently selected from hydrogen or a C<sub>1-3</sub> aliphatic group.

2. (Original) The compound of claim 1, wherein R<sup>y</sup> is a C<sub>1-4</sub> aliphatic group.


3. (Original) The compound of claim 2, wherein R<sup>y</sup> is selected from methyl, ethyl, cyclopropyl, *tert*-butyl, or isopropyl.

Applicants: Cornelia J. Forster et al.  
Application No.: 10/632,340

4. (Original) The compound according to claim 3, wherein  $R^y$  is selected from methyl, cyclopropyl, or *tert*-butyl.
- 5-6. (Canceled)
7. (Original) The compound according to claim 1, wherein  $R^1$  is hydrogen.
8. (Original) The compound according to claim 1, wherein  $R^1$  is fluorine.
9. (Original) The compound according to claim 1, wherein  $R^y$  is a  $C_{1-4}$  aliphatic group substituted with a 6-membered saturated ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
10. (Original) The compound according to claim 9, wherein  $R^y$  is a  $C_{1-4}$  aliphatic group substituted with a morpholinyl, piperidinyl, or piperazinyl ring
11. (Original) The compound according to claim 1, wherein  $R^y$  is a  $C_{1-4}$  aliphatic group substituted with  $N(R^2)_2$ .
12. (Previously presented) A compound selected from the group consisting of:




I-1




I-3


Applicants: Cornelia J. Forster et al.  
Application No.: 10/632,340




I-5




I-6




I-7




I-8




I-9




I-10




I-11




I-12



I-13




I-14




I-15


Applicants: Cornelia J. Forster et al.  
 Application No.: 10/632,340



I-16



I-17



and I-18.

13. (Previously presented) A pharmaceutically acceptable composition comprising a compound according to claim 1, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

14. (Previously presented) The composition according to claim 13, additionally comprising an additional therapeutic agent selected from an agent for treating stroke, an antidepressant, an anti-psychotic agent, or an agent for treating diabetes.

15-17. (Canceled)

18. (Previously presented) A method of treating a disease, disorder, or condition selected from diabetes, schizophrenia, anxiety, bipolar disorder, stroke, in a patient in need thereof, comprising administering the composition according to claim 13 to said patient.

19-22. (Canceled)

23. (Previously presented) The method according to claim 18, comprising the additional step of administering to said patient an additional therapeutic agent selected from an agent for treating stroke, an antidepressant, an anti-psychotic agent, or an agent for treating diabetes, wherein:

Applicants: Cornelia J. Forster et al.  
Application No.: 10/632,340

said additional therapeutic agent is appropriate for the disease being treated;

and

said additional therapeutic agent is administered together with said composition as a single dosage form or separately from said composition as part of a multiple dosage form.

24. (Previously presented) The compound of claim 12, selected from the group consisting of I-1, I-3, I-5, I-6, and I-7.